EMA committee recommends orphan drug status for Erytech product
The drug, which is used to treat sickle cell disease, increases the oxygenation properties of red blood cells by reducing their oxygen-hemoglobin affinity and allowing them to release
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
As part of the agreement, Full Spectrum Genetics protein analysis and engineering platform, MapEng, and BioBlocks’ fragment based drug discovery platform technology,Fragment-to-Lead, will be combined. The technologies will